MOR agonists have been demonstrated to alleviate colitis in preclinical models of IBD by dampening inflammatory cytokine production, including TNF-α [10], while chronic opioid use in IBD patients correlates with adverse clinical outcomes [11]. The gene discussed is TNF; the disease is colitis.